Search

everythinglearnresearchcommunity

for

Search:↓

The user has been using oral finasteride for over a year and recently added GHK-CU for two months, seeing progress but seeking further improvement, especially on the hairline. They discuss sourcing GHK-CU, its effects, and the importance of third-party testing, while considering additional treatments like dutasteride and hair transplants for better results.

The user is using a hair loss treatment regimen that includes applying various topical solutions and taking oral medication. They are mixing their topical treatments to save time but are concerned about the effectiveness of the treatments when combined and stored.

The user shared progress after two months using a topical formulation containing Dutasteride 0.25%, Minoxidil 5%, Cetirizine 1%, Melatonin 0.5%, Caffeine 2%, and Latanoprost 0.005%. The focus is on hair loss treatment results.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.

The user shared a 4-month update on their hair loss treatment, using 2.5 mg OM daily, 0.5 mg Dutasteride three times a week, and a multivitamin with biotin. They provided progress pictures to show their results.

Carpronium chloride 5% is a hair growth treatment in Japan, considered less effective than minoxidil or finasteride. Some users report moderate success with it, but its efficacy is not well-verified.

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.

Finasteride and Dutasteride will remain accessible in the EU despite objections from France and Belgium. Users discuss the ease of obtaining these medications in different countries and express relief and support for the EU's decision.

OP has been using daily oral finasteride 1.25mg for 5 months with noticeable progress and no side effects. They chose this dosage by cutting 5mg pills into quarters due to cost.

A user shared their positive experience with the telehealth service DocBright, highlighting its affordability and effectiveness in prescribing finasteride, oral minoxidil, and ketoconazole. They noted the service's unique ability to provide a prescription at age 17 but criticized the unprofessional communication with the dermatologist.

The conversation is about someone using Dutasteride, oral Minoxidil, and Tretinoin for hair loss, and they also stopped antipsychotics and treated an H. pylori infection. They feel there has been progress in their hair growth over two months.

A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.

The user stopped finasteride for family planning but plans to restart it and is considering dutasteride. Users discuss the safety of finasteride during family planning, with some sharing experiences of having healthy children while on the medication.

Dutasteride significantly improved hair health and reduced shedding for a woman with PCOS and hyperandrogenism, without causing depression or anxiety, unlike finasteride. Dutasteride also helped with PMDD symptoms and had no side effects, though it changed hair texture.

PP405 might take 3-4 years to be available, but some claim Everychem offers a similar product, though its effectiveness is debated. Users discuss the risks of using untested grey market products and the potential for adverse effects.

PP405 is expected to finish Phase 2 trials in late 2025, with potential market availability around 2028-2029 if all goes well. Current treatments like finasteride and minoxidil are still popular, while new options like KX-826 and Breezula are anticipated soon.

A poem humorously suggests hope for a new hair loss treatment, PP405, while users debate the effectiveness and side effects of current treatments like Finasteride. Concerns are raised about Finasteride's side effects, especially for young users, and skepticism about new treatments is expressed.

A user shared their positive experience with a 4750 graft hair transplant at Dr. Orçun Clinic in Istanbul, including a high-quality exosome treatment. Despite skepticism and accusations of advertising, the user expressed satisfaction with the natural-looking results and the doctor's personal involvement.

PP405 increased hair density by 20% in 31% of participants, but results are considered underwhelming. Minoxidil and finasteride are seen as more effective treatments.

Scientists at UCLA have developed a promising treatment for male pattern baldness using a molecule called PP405, which can potentially stimulate dormant hair follicles. Initial trials showed significant results within a week, but larger clinical trials are needed to confirm its efficacy and safety.

PP405 is viewed skeptically, with some seeing it as overhyped and potentially ineffective compared to existing treatments like minoxidil and finasteride. While it shows some promise in activating dormant hair follicles, many believe it won't replace hair transplants or significantly outperform current options.

A 24-year-old male combines topical and oral finasteride with minoxidil to combat hair loss, experiencing heavy shedding but no significant side effects. Other users share their experiences with similar combinations, including using dutasteride and ketoconazole, emphasizing that personalized routines can be effective.

The user plans to improve hair density using Koshine, Avodart (1.5-2.5mg daily), and 5mg OM daily. They previously used finasteride, minoxidil, dutasteride, and fluridil with some improvement.

A user switched from finasteride to dutasteride and from topical to oral minoxidil, experiencing significant hair shedding. They plan to continue this regimen for a year before deciding on any changes.

Visible hair improvement after 10 weeks using minoxidil, estradiol enanthate, acetophenide algestone, and bicalutamide. The user is a 25-year-old male with reduced testosterone levels, expressing a preference for less masculinity.

OP bought Koshine x826 and plans to update on its effectiveness, currently using fluridil. OP couldn't tolerate RU or DUT, while another user mixes Dutasteride with Koshine x826 weekly without side effects.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss. PP405 is still under evaluation for safety.

The conversation discusses the removal of Breezula phase II 12-month results by Cassiopea and the search for the original data. Concerns were raised about potential negative long-term effects on hair growth, such as androgen receptor upregulation.